Ulisse Biomed S.p.A. (UBM.MI)

EUR 0.78

(-2.26%)

Market Cap (In EUR)

17.18 Million

Revenue (In EUR)

66.2 Thousand

Net Income (In EUR)

-4.79 Million

Avg. Volume

8437.00

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.76-1.9
PE
-
EPS
-
Beta Value
0.622
ISIN
IT0005451213
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Nicola Basile
Employee Count
-
Website
https://www.ulissebiomed.com
Ipo Date
2021-08-09
Details
Ulisse Biomed S.p.A., a healthcare biotech company, provides diagnostic platforms and products. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It also provides various tests and reagents for sexually transmitted diseases and HPV for oropharyngeal cancer. In addition, the company's platforms also comprise NanoHybrid, a DNA/PNA based multi-modal biomolecule platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.